Epidermal growth factor receptor mutations in non-small cell lung cancer: A basic science discovery with immediate clinical impact

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A large body of preclinical work suggested that the epidermal growth factor receptor (EGFR) would be a successful target for therapy against non-small cell lung cancer (NSCLC), and this led to the development of oral, selective EGFR tyrosine kinase inhibitors (TKI) that improve symptoms and survival in patients with advanced NSCLC. However, not all patients benefit from this treatment, and there has been great interest in identifying the molecular correlates that predict for response to these agents. The recent detection of somatic mutations in EGFR that predict for response to the EGFR tyrosine kinase inhibitors has excited the scientific community. This discovery has far-reaching implications, not only for lung cancer patients treated with an EGFR TKI but also for future drug development in all malignancies.

Original languageEnglish (US)
Pages (from-to)139-149
Number of pages11
JournalAmerican Journal of the Medical Sciences
Volume331
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Protein-Tyrosine Kinases
Lung Neoplasms
Survival
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Epidermal growth factor receptor
  • Lung neoplasms
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{d1dfc07f4d6744229169fe9d9cf83674,
title = "Epidermal growth factor receptor mutations in non-small cell lung cancer: A basic science discovery with immediate clinical impact",
abstract = "A large body of preclinical work suggested that the epidermal growth factor receptor (EGFR) would be a successful target for therapy against non-small cell lung cancer (NSCLC), and this led to the development of oral, selective EGFR tyrosine kinase inhibitors (TKI) that improve symptoms and survival in patients with advanced NSCLC. However, not all patients benefit from this treatment, and there has been great interest in identifying the molecular correlates that predict for response to these agents. The recent detection of somatic mutations in EGFR that predict for response to the EGFR tyrosine kinase inhibitors has excited the scientific community. This discovery has far-reaching implications, not only for lung cancer patients treated with an EGFR TKI but also for future drug development in all malignancies.",
keywords = "Epidermal growth factor receptor, Lung neoplasms, Tyrosine kinase inhibitors",
author = "Dowell, {Jonathan E.} and Caplan, {Norman M.} and Palmer, {Biff F.}",
year = "2006",
month = "3",
doi = "10.1097/00000441-200603000-00006",
language = "English (US)",
volume = "331",
pages = "139--149",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Epidermal growth factor receptor mutations in non-small cell lung cancer

T2 - A basic science discovery with immediate clinical impact

AU - Dowell, Jonathan E.

AU - Caplan, Norman M.

AU - Palmer, Biff F.

PY - 2006/3

Y1 - 2006/3

N2 - A large body of preclinical work suggested that the epidermal growth factor receptor (EGFR) would be a successful target for therapy against non-small cell lung cancer (NSCLC), and this led to the development of oral, selective EGFR tyrosine kinase inhibitors (TKI) that improve symptoms and survival in patients with advanced NSCLC. However, not all patients benefit from this treatment, and there has been great interest in identifying the molecular correlates that predict for response to these agents. The recent detection of somatic mutations in EGFR that predict for response to the EGFR tyrosine kinase inhibitors has excited the scientific community. This discovery has far-reaching implications, not only for lung cancer patients treated with an EGFR TKI but also for future drug development in all malignancies.

AB - A large body of preclinical work suggested that the epidermal growth factor receptor (EGFR) would be a successful target for therapy against non-small cell lung cancer (NSCLC), and this led to the development of oral, selective EGFR tyrosine kinase inhibitors (TKI) that improve symptoms and survival in patients with advanced NSCLC. However, not all patients benefit from this treatment, and there has been great interest in identifying the molecular correlates that predict for response to these agents. The recent detection of somatic mutations in EGFR that predict for response to the EGFR tyrosine kinase inhibitors has excited the scientific community. This discovery has far-reaching implications, not only for lung cancer patients treated with an EGFR TKI but also for future drug development in all malignancies.

KW - Epidermal growth factor receptor

KW - Lung neoplasms

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33645101097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645101097&partnerID=8YFLogxK

U2 - 10.1097/00000441-200603000-00006

DO - 10.1097/00000441-200603000-00006

M3 - Article

C2 - 16538075

AN - SCOPUS:33645101097

VL - 331

SP - 139

EP - 149

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 3

ER -